E-EDV-D682 Drug Asset Due Diligence Report 2026

This E-EDV-D682 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

174

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether E-EDV-D682 can convert its Small molecule drug profile and EGFR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	E-EDV-D682 (query alias: E-EDV-D682)
Modality / target	Small molecule drug; EGFR; EGFR modulators
Highest global status	Phase 1/2
Originator	EnGeneIC Pty Ltd.
Active developers	EnGeneIC Pty Ltd.

The MCP disease footprint includes Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07049055	Phase 1/2	Recruiting	144	Primary endpoint not disclosed in English source
ACTRN12625000203459	Phase 1/2	Recruiting	160	Primary endpoint not disclosed in English source
ACTRN12619000385145	Phase 1/2	Stopped early	80	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase I/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and glycolipid-packaged nanocells

Phase 1/2; n=25; evaluation: Positive. Reported fields: TRAE = 76.0 % ; -

Interim data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α-galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer.

Phase 1; n=9; evaluation: Positive. Reported fields: IRR = A minority of patients experienced G1 infusion reactions, which responded promptly to supportive treatment

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

E-EDV-D682 addresses Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 174 matched transaction record(s) under the scope “target-level comparable: EGFR.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: EGFR records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-09-03	HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy	Phase 1/2	US$110.0M upfront; US$1,185.0M milestones; US$1,295.0M stated total
2026-08-17	Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform	Discontinued	US$322.0M stated total
2026-07-21	Transaction title not available in English source	NDA/BLA	US$10.3M upfront; US$304.4M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Bispecific b7h3/EGFR-binding protein and conjugate thereof”. The milestone feed surfaced a patent-application signal described as “Combination therapy involving antibody-drug conjugates against claudin18.2 and PD1/PD-l axis inhibitors for treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Ligand-drug conjugate and use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO